LifeMD’s (LFMD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of LifeMD (NASDAQ:LFMD) in a report issued on Thursday, Marketbeat.com reports. They currently have a $9.00 target price on the stock.

LFMD has been the subject of a number of other research reports. UBS Group reiterated a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. B. Riley Financial began coverage on shares of LifeMD in a research note on Friday, September 11th. They set a “buy” rating and a $8.00 price objective for the company. Lake Street Capital set a $5.00 target price on shares of LifeMD in a report on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of LifeMD in a report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.57.

LifeMD Stock Performance

Shares of NASDAQ:LFMD opened at $3.22 on Thursday. LifeMD has a one year low of $2.56 and a one year high of $7.32. The stock has a fifty day moving average of $3.52 and a 200-day moving average of $4.00. The company has a market capitalization of $155.20 million, a PE ratio of -64.39 and a beta of 2.04.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The company had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. As a group, research analysts forecast that LifeMD will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in LifeMD by 10.1% during the 1st quarter. Bank of America Corp DE now owns 48,703 shares of the company’s stock worth $176,000 after acquiring an additional 4,465 shares during the period. Bank of New York Mellon Corp grew its stake in LifeMD by 2.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 246,586 shares of the company’s stock valued at $1,018,000 after acquiring an additional 5,651 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of LifeMD in the 2nd quarter valued at about $25,000. R Squared Ltd acquired a new position in shares of LifeMD in the 1st quarter valued at about $41,000. Finally, Corient Private Wealth LP purchased a new stake in shares of LifeMD in the second quarter worth approximately $63,000. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc (NASDAQ: LFMD) is a U.S.-based telehealth company that provides virtual healthcare services through its digital platform. The company connects patients with licensed healthcare professionals through online consultations, enabling access to medical care, prescriptions, ongoing treatment and care-management services without requiring an in-person visit.

LifeMD offers services across several areas, including virtual primary care, men’s and women’s health, dermatology, mental health and weight management.